Drug Profile


Alternative Names: Daranide; Dichlorphenamide; Keveyis

Latest Information Update: 27 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Taro Pharmaceutical Industries
  • Class Antiglaucomas; Small molecules; Sulfonamides
  • Mechanism of Action Carbonic anhydrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Paralysis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Paralysis
  • Market Withdrawal Glaucoma

Most Recent Events

  • 26 Dec 2016 Diclofenamide licensed to Strongbridge Biopharma in USA
  • 21 Sep 2015 Launched for Paralysis in USA (PO)
  • 10 Aug 2015 Registered for Paralysis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top